Active, not recruitingPHASE1, PHASE2NCT01757626

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Studying Ependymoblastoma

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigator: Brian Kushner, MD
Memorial Sloan Kettering Cancer Center
Intervention: Hu3F8 With GM-CSF(biological)
Enrollment: 186 target
Eligibility: 1 years · All sexes
Timeline: 2012 – 2026

Study locations (1)

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Collaborators

Y-mAbs Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01757626 on ClinicalTrials.gov

Other trials for Ependymoblastoma

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT03363373
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics

See all trials for Ependymoblastoma →

← Back to all trials